Phio Pharmaceuticals
PHIO
7 hedge funds and large institutions have $647K invested in Phio Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 3 closing their positions.
125% more capital invested
Capital invested by funds: $287K → $647K (+$360K)
0% more funds holding
Funds holding: 7 → 7 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$626K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$61.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$7.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$16K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
-$12K |
| 3 |
IP
Intellectus Partners
San Francisco,
California
|
-$9K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.36K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $520K | +$626K | +265 | New |
|
2
SG Americas Securities
New York
| $54K | – | – | – |
|
|
CH
3
CVI Holdings
Wilmington,
Delaware
| $51K | +$61.4K | +26 | New |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| $9K | -$2.36K | -1 | -20% |
|
|
5
Citadel Advisors
Miami,
Florida
| $7K | +$7.09K | +3 | New |
|
|
EDRH
6
Edmond de Rothschild Holding
Chambesy,
Switzerland
| $4K | – | – | – |
|
7
Morgan Stanley
New York
| $2K | – | – | – |
|
|
8
HighTower Advisors
Chicago,
Illinois
| – | -$12K | -2 | Closed |
|
|
TSS
9
Two Sigma Securities
New York
| – | -$16K | -2 | Closed |
|
|
IP
10
Intellectus Partners
San Francisco,
California
| – | -$9K | -1 | Closed |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$1K | – | – |
|
PHIO Hedge Fund Activity: Q4 2018 in Review
7 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q4 2018, worth a combined $647K — up 125% from $287K a quarter earlier.
Fund positioning in PHIO was balanced in Q4 2018: 3 funds opened new positions, 3 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $626K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $16K sold.
- 7 institutional investors held Phio Pharmaceuticals (PHIO) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $647K of Phio Pharmaceuticals stock for Q4 2018, up 125% quarter-over-quarter.
- 3 funds opened new Phio Pharmaceuticals positions in Q4 2018 and 3 closed out, a net change of 0 holders.
- The largest Phio Pharmaceuticals buyer in Q4 2018 was Sabby Management, an estimated $626K added.
- The largest Phio Pharmaceuticals seller in Q4 2018 was Two Sigma Securities, an estimated $16K sold.
Based on aggregated 13F filings for Q4 2018.